Why the study?
Does continuous infusion therapy reduce toxicity and preserve efficacy compared to classical intravenous bolus injection in patients receiving doxorubicin or daunorubicin?
Does continuous infusion therapy reduce toxicity and preserve efficacy compared to classical intravenous bolus injection in patients receiving doxorubicin or daunorubicin?
While continuous infusion of doxorubicin may reduce toxicity compared to bolus injection, comparative phase III trials are needed to confirm preservation of efficacy.
Answers are grounded in this paper and cite their sources.
May reduce doxorubicin toxicity via continuous infusion; leaves open efficacy preservation without phase III data.
In order to achieve a better therapeutic index of anticancer drugs, numerous authors are using continuous infusion therapy rather than classical intravenous bolus injection. In the case of doxorubicin or daunorubicin numerous experimental data have been published, which could provide a rationale to this clinical problem. However, due to the variety of the approaches used, the results are inconsistent and no definitive conclusion can be drawn. Several clinical phase I and II trials have been performed since 1980; they show that the toxicity of doxorubicin may be reduced by the use of continuous infusion, but the preservation of the efficacy of the drug has never been proved. Comparative phase III trials are required before this schedule of administration become routine procedure for this drug.
No takes yet. Share an insight, caveat, or question.
Jacques Robert (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: